Search

Search results

580 results found

A Cell-Based High-Throughput Screening for Inducers of Myeloid Differentiation.

Publication: Journal Article

Radomska, Hanna S, Finith Jernigan, Sohei Nakayama, Susan E Jorge, Lijun Sun, Daniel G Tenen, and Susumu S Kobayashi. 2015. “A Cell-Based High-Throughput Screening for Inducers of Myeloid Differentiation.”. Journal of Biomolecular Screening 20 (9): 1150-9.

Syntheses and antitumor activities of N'1,N'3-dialkyl-N'1,N'3-di-(alkylcarbonothioyl) malonohydrazide: the discovery of elesclomol.

Publication: Journal Article

Chen, Shoujun, Lijun Sun, Keizo Koya, Noriaki Tatsuta, Zhiqiang Xia, Timothy Korbut, Zhenjian Du, et al. 2013. “Syntheses and Antitumor Activities of N’1,N’3-Dialkyl-N’1,N’3-Di-(alkylcarbonothioyl) Malonohydrazide: The Discovery of Elesclomol.”. Bioorganic & Medicinal Chemistry Letters 23 (18): 5070-6.

The synthesis of neoglycophospholipid conjugates via reductive amination of omega-oxoalkylglycosides and phosphatidylethanolamines.

Publication: Journal Article

Sun, L, and E L Chaikof. 1998. “The Synthesis of Neoglycophospholipid Conjugates via Reductive Amination of Omega-Oxoalkylglycosides and Phosphatidylethanolamines.”. Carbohydrate Research 307 (1-2): 77-81.

Neoglycophospholipids with alkyl spacers: synthesis via an improved reductive amination and monolayer properties.

Publication: Journal Article

Sun, L, and E L Chaikof. 1997. “Neoglycophospholipids With Alkyl Spacers: Synthesis via an Improved Reductive Amination and Monolayer Properties.”. Bioconjugate Chemistry 8 (4): 567-71.

In silico discovery and therapeutic potential of IDO1 and TDO2 inhibitors.

Publication: Journal Article

Jernigan, Finith E, and Lijun Sun. 2017. “In Silico Discovery and Therapeutic Potential of IDO1 and TDO2 Inhibitors.”. Future Medicinal Chemistry 9 (12): 1309-11.

Alejandra and Emily dive into research discussions during an engaging poster session

News: September 05, 2024

PGC-1α

Page

Siling Li, MSc

Person: Lead Statistician

Siling has 3 years of experience in clinical trials and 3 years in CMS claims data research. She is skilled in statistical analysis and programming using SAS and R to investigate health outcomes and disparities. Her work spans a variety of areas, including cardiovascular disease, hypertension, and...

miR-155 as a novel clinical target for hematological malignancies.

Publication: Journal Article

Witten, Lisa, and Frank J Slack. 2020. “MiR-155 As a Novel Clinical Target for Hematological Malignancies.”. Carcinogenesis 41 (1): 2-7.

Tumor penetrating nanomedicine targeting both an oncomiR and an oncogene in pancreatic cancer.

Publication: Journal Article

Gilles, Maud-Emmanuelle, Liangliang Hao, Kaelyn Brown, Jihoon Lim, Sangeeta N Bhatia, and Frank J Slack. 2019. “Tumor Penetrating Nanomedicine Targeting Both an OncomiR and an Oncogene in Pancreatic Cancer.”. Oncotarget 10 (51): 5349-58.